{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4"},{"groupId":"OG001","value":"92.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"281"}],"units":"Participants"}],"description":"Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a \\>=50% reduction in the size of soft tissue plasmacytomas is also required.","groups":[{"description":"Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg weekly for participants greater than \\[\\>\\] 75 years old or with a body mass index less than \\[\\<\\] 18.5 kilograms per meter square \\[kg/m\\^2\\]).","id":"OG000","title":"Lenalidomide, Low-dose Dexamethasone (Rd)"},{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks, each 28-day cycle); once only on Day 1 during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone was administered at a total dose of 40 mg weekly (or 20 mg weekly for participants \\>75 years old or with a body mass index \\< 18.5 kg/m\\^2).","id":"OG001","title":"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)"}],"paramType":"NUMBER","populationDescription":"Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression (up to 21 months)","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}